Awaiting development: Guidance and quality standards

Showing 151 to 160 of 285

Guidance and quality standards awaiting development
Title	Type
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance
Nirogacestat for treating desmoid tumours TSID 12039	Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659	Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475	Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103	Technology appraisal guidance
Obinutuzumab for treating lupus nephritis ID 6420	Technology appraisal guidance